Diabetes

04/18/2012 - Web-Based

Instructions:

This survey is designed to determine the educational effectiveness of this WebCAST, with aggregated results from this Phase I survey compared to results from the post-program Phase II surveys.

To complete this Clinical Performance and Knowledge Gap Assessment Tool, select your answer for each of the questions below. There is only one correct answer for each question

Thank you,
CMEducation Resources

A. Clinical Questions

1. Which of the following statements about the micro- and macrovascular risks associated with type 2 diabetes is TRUE?

2. All of the following are appropriate goals for diabetes management EXCEPT:

3. Less stringent A1c goals may be appropriate for which of the following patients?

4. Which of the following statements regarding therapeutic goals for glycemic indicators outlined by national treatment guidelines is FALSE?

5. Which of the following statements regarding key considerations in the management of type 2 diabetes is FALSE?

6. Progression of type 2 diabetes is characterized by which of the following features?

7. Which of the following is an appropriate potential new strategy for managing disease progression in patients with type 2 diabetes?

8. AJ is a 58-year old man with a recent history of type 2 diabetes. After being well controlled on metformin (2000 mg per day) treatment alone for 1 year, his latest A1c is 8.2%. Which of the following treatment options would be LEAST appropriate for AJ?

9. Which of the following statements about recent clinical trial findings related to the use of insulin in patients with type 2 diabetes is FALSE?

10. BP is a 42-year old man who was diagnosed with diabetes and started on metformin therapy 4 months ago. His current HbA1c is 8.2%. According to the ADA/EASD consensus algorithm, which of the following would be the LEAST appropriate next step in therapy for BP?

11. Which of the following statements regarding the ADA/EASD guidelines and treatment algorithm is TRUE?

12. Which of the following statements about the pharmacokinetic characteristics of insulin glargine is FALSE?

13. Which of the following statements regarding insulin glargine in type 2 diabetes is TRUE?

14. Which of the following options is the LEAST appropriate way to initiate basal insulin in a patient with type 2 diabetes?

15. Which of the following statements regarding the early initiation, addition, or intensification of insulin therapy in type 2 diabetes is FALSE?

16. All of the following are potential barriers associated with insulin initiation in diabetes, EXCEPT:

17. When initiating insulin therapy in patients with type 2 diabetes, patients should be advised to maintain regular eating habits and exercise schedules, centered around their insulin treatment regimen.

18. All of the following should be a primary consideration when designing/adjusting insulin regimens in patients with type 2 diabetes EXCEPT:

19. TK is a 64-year old woman with a 3-year history of type 2 diabetes. Despite losing 10 pounds in the past year, her most recent A1c is 7.9%. Her current medication regimen includes metformin and a sulfonylurea. You decide to add insulin treatment to her regimen. Which of the following is the MOST appropriate next step in therapy for TK?

20. Rapid-acting insulin analogues control post-prandial glucose levels better than regular insulin, but cause more hypoglycemia.

21. Which of the following is LEAST likely to contribute to the general delay in initiating insulin therapy in patients with type 2 diabetes?

22. In which of the following patients with type 2 diabetes would it be MOST appropriate to initiate insulin therapy?

23. GG is a 68-year old woman with a 3-year history of type 2 diabetes. Her A1c is 8.1% and she is currently on metformin, a sulfonylurea, and bedtime basal insulin. Her fasting plasma glucose levels are consistently around 110 mg/dL and her postprandial levels are around 180 mg/dL. Which of the following is the MOST appropriate next step in therapy for GG?

B. Subjective Practice Assessment/Attitudes/Perceptions/Demographic

1. Approximately how many patients with type 2 diabetes do you see EACH WEEK?

2. When managing your patients with type 2 diabetes, to which of the following national guidelines/recommendations are you most likely to refer?

3. How confident are you in your ability to appropriately manage your patients with type 2 diabetes who are not achieving glycemic targets?

4. How confident are you in your ability to set appropriate treatment targets in your patients with type 2 diabetes based on their individualized needs?

5. How confident are you in your ability to appropriately identify patients with type 2 diabetes who may benefit from insulin therapy?

6. Currently, how often do you initiate insulin therapy as second or third-line treatments in your patients with type 2 diabetes who are not achieving adequate glycemic control on oral therapies?

Your Information

Please provide your email address to complete this survey form. Completed surveys will be assigned an ID number that will allow us to process your survey responses anonymously and compare pooled pre-program survey results with post-program survey results to measure ongoing, enduring learning. Your email address will be used to communicate information on future surveys and send a final outcomes report. Thank you.